Current Treatment Landscape of CIDP


Dr Lewis gives an overview of the current treatment landscape of CIPD, including response rates to available treatments.

This is a video synopsis/summary of a panel discussion involving Richard Lewis, MD.

In the discussed transcript, the speaker emphasizes 3 established treatments for a medical condition, avoiding specific drug and medical terminology. These treatments include intravenous immunoglobulin, corticosteroids, and plasma exchange, each exhibiting varying effectiveness and potential drawbacks. Notably, these treatments collectively demonstrate efficacy in approximately 70% of patients. The speaker advises attempting different treatments if one proves ineffective, suggesting a trial-and-error approach.

Furthermore, the speaker mentions immunosuppressive agents like cyclosporine and cyclophosphamide as alternative treatments, acknowledging their slow onset but potential for reducing corticosteroid dosage. Other investigational treatments, such as FcRn (neonatal Fc) receptor inhibitors, complement inhibitors, and B-cell depleting treatments like rituximab, show promise but lack conclusive evidence.

Beyond primary treatments, the transcript highlights the absence of proven secondary treatments, emphasizing the importance of patient-physician discussions in selecting alternative approaches. The speaker stresses the need for a second opinion from specialists when progressing beyond initial treatment, particularly if the current approach fails, underscoring the complexity and individualized nature of managing the condition.

Video synopsis is AI-generated and reviewed by NeurologyLive editorial staff.

Related Videos
Sanjay R. Patel, MD, MS
Patricia K. Coyle, MD
Video 2 - 5 KOLs are featured in "Natural History of Spinal Muscular Atrophy"
Video 1 - 5 KOLs are featured in "Clinical Features and Phenotypes of Spinal Muscular Atrophy"
Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN
© 2024 MJH Life Sciences

All rights reserved.